Show Notes
his week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions that get to the heart of metabolic health. The team explains the real difference between meals and snacks, discusses whether GLP-1 medications can be appropriate for children in complex cases, explores why some people appear to be “non-responders” to Wegovy, and breaks down why alarming headlines about rapid weight regain miss the bigger metabolic picture. They also explain how to set a goal weight using body composition, labs, and overall health—rather than the scale alone. Key Questions Answered • What separates a meal from a snack metabolically? • Why can grazing all day backfire—even with healthy food? • Are GLP-1s ever appropriate for kids? • Why do some people feel hungrier as GLP-1 doses increase? • How are PCOS and insulin dysregulation connected? • What is a mixed meal tolerance test, and why does it matter? • Do GLP-1 users really regain weight faster? • How should goal weight be determined after major weight loss? Key Takeaways • Meals provide structure; snacks prevent long gaps—both matter. • GLP-1 “non-response” often signals deeper metabolic issues. • Weight regain reflects underlying dysfunction, not personal failure. • Maintenance dosing must be individualized. • Body composition matters more than BMI or scale weight. Dr. Cooper’s Actionable Tips • Eat structured meals with carbs, protein, and fats. • Use snacks strategically to avoid long gaps. • Ask about deeper glucose/insulin testing when progress stalls. • Prioritize DEXA body composition over scale-based goals. • Avoid compounded GLP-1s—especially in children. Notable Quote “If you stop treating the metabolic dysfunction, the dysfunction is still there—and the body will drive weight back to where it was headed all along.” —Dr. Emily Cooper Links & Resources Podcast Home: https://fatsciencepodcast.com/ Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdf Cooper Center: https://coopermetabolic.com/podcast/ Resources from Dr. Cooper: https://coopermetabolic.com/resources/ Submit a Question: [email protected] Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.
More from Fat Science
Wondering why weight stalls on treatment? Dr. Emily Cooper explains how the brain defends set points and why eating less stops progress. Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener letters from around the world. The conversation addresses why athletic men with a BMI of 27 can still show high visceral fat on a DEXA scan, how medications defend metabolic set points, and why intentional undereating triggers starvation responses. The team also examines global access to metabolic treatments, dual incretin agonists versus single agonists, artificial sweeteners, and how to interpret two-hour insulin and glucose tolerance curves. Key Takeaways Rapid weight reduction without adequate nutrition can cause lean mass loss and trigger metabolic defense mechanisms. Dual incretin therapies stimulate GIP receptors far more than GLP-1 receptors compared to natural human hormones, creating different patient responses. Intentional calorie restriction reduces natural incretin production and can impair metabolic signaling, making mechanical fueling essential. Fasting insulin suppression combined with pre-diabetes indicators can reflect the brain pulling glucose during periods of low carbohydrate intake. Resources Mentioned Diabesity Foundations Course Cooper Center for Metabolism Diabesity Institute Connect with Us Podcast Home:fatsciencepodcast.com Cooper Center for Metabolism:coopermetabolic.com Diabesity Institute: diabesityinstitute.org Resources from Dr. Cooper:coopermetabolic.com/resources Join Our Community:patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations. Produced by: Podcast Impact Studio https://podcastimpactstudio.com
What do new drug reports really mean for your treatment? Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues. KEY TAKEAWAYS Understanding the difference between efficacy estimand and treatment policy estimand.
Can metabolic dysfunction be the cause of anxiety?
What's the back-to-school metabolism shift all about?